Thrombocytopenia: Clinical Trials

443 completed, 190 unknown, 146 recruiting, 90 terminated. 347 Phase 2, 203 Phase 3, 110 Phase 1, 83 Not applicable, 55 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	347	Completed 140, Unknown 70, Recruiting 49, Terminated 42, Not yet recruiting 20, Withdrawn 17, Active not recruiting 9
Phase 3	203	Completed 102, Unknown 29, Terminated 25, Recruiting 21, Active not recruiting 10, Withdrawn 10, Not yet recruiting 6
Phase 1	110	Completed 53, Recruiting 20, Terminated 15, Not yet recruiting 8, Unknown 8, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 1
Not applicable	83	Completed 33, Recruiting 18, Not yet recruiting 11, Unknown 10, Withdrawn 5, Active not recruiting 3, Terminated 3
Phase 4	55	Completed 21, Unknown 19, Recruiting 6, Terminated 5, Withdrawn 3, Not yet recruiting 1
Early Phase 1	16	Completed 5, Recruiting 4, Unknown 3, Not yet recruiting 2, Withdrawn 2

Follow Thrombocytopenia: new trials by email Literature Review of Thrombocytopenia trials Research Report on Thrombocytopenia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome	Phase 2	Not yet recruiting	NovelMed Therapeutics	12	2027-11-01	2026-04-13
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)	Phase 2	Not yet recruiting	Novartis Pharmaceuticals	36	2027-02-08	2026-06-25
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP)	Phase 1	Not yet recruiting	RiboX Therapeutics Ltd.	27	2027-02-01	2026-09-23
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)	Phase 1 / Phase 2	Not yet recruiting	Cullinan Therapeutics Inc.	72	2026-12-01	2026-07-31
Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2	Not yet recruiting	The First Affiliated Hospital of Henan University of Science and Technology	87	2026-11-01	2026-09-21
TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia	Phase 1 / Phase 2	Not yet recruiting	TargED Biopharmaceuticals B.V.	70	2026-10-31	2026-09-29
Neonatal Thrombocytopenia in the NICU Thrombocytopenia, Neonatal Thrombocytopenia		Not yet recruiting	Assiut University	120	2026-10-20	2026-10-20
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program No Intervention - Thrombotic Thrombocytopenic Purpura (TTP)		Recruiting	Takeda	94	2026-09-24	2026-10-20
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia Additional blood sample - Thrombocytopenia, Platelet Transfusion		Recruiting	Centre Hospitalier Annecy Genevois	410	2026-09-18	2026-10-22
Selective Mediterranean Diet in Immune Thrombocytopenia Selective Mediterranean Diet, Standard Pharmacological Therapy for ITP - Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura	Not applicable	Not yet recruiting	Assiut University	60	2026-09-01	2026-09-03
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases CHT105 - Immune Thrombocytopenia (ITP)	Not applicable	Not yet recruiting	Nanjing Miracle Biotechnology Co., Ltd.	24	2026-09-01	2026-09-10
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy blood draw, urine collection - Thrombotic Microangiopathies	Not applicable	Not yet recruiting	Sofie Dhaese	40	2026-09-01	2026-07-15
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy iptacopan - Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)	Not applicable	Recruiting	First Affiliated Hospital of Zhejiang University	30	2026-08-25	2026-08-26
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia	Phase 3	Recruiting	Amgen	126	2026-08-21	2026-09-17
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)	Phase 2	Recruiting	Novartis Pharmaceuticals	164	2026-08-04	2026-10-22
Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation MegaLT Injection - Thrombocytopenia, Hematologic Malignacies	Early Phase 1	Not yet recruiting	Anhui Provincial Hospital	7	2026-07-31	2026-07-10
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia	Phase 1 / Phase 2	Recruiting	CRISPR Therapeutics AG	60	2026-07-17	2026-10-20
Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. Nplate, NaCl %0.9 - Chirurgical Intervention, Thrombocytopaenia	Phase 2	Recruiting	Nantes University Hospital	136	2026-07-16	2026-07-24
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)	Phase 1	Active not recruiting	Oscotec Inc.	48	2026-07-10	2026-09-01
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP Eltrombopag - Immune Thrombocytopenia	Phase 2	Not yet recruiting	Institute of Hematology & Blood Diseases Hospital, China	40	2026-07-10	2026-07-07

Showing 20 of 1007. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (481)  ·  Purpura, Thrombotic Thrombocytopenic (65)  ·  Thrombotic Microangiopathies (49)  ·  Atypical Hemolytic Uremic Syndrome (45)  ·  Anemia (41)  ·  Hematologic Diseases (35)  ·  Hemorrhage (32)  ·  Neutropenia (30)  ·  Purpura, Thrombocytopenic (30)  ·  Myelodysplastic Syndromes (29)  ·  Autoimmune Diseases (26)  ·  Hemolytic-Uremic Syndrome (26)  ·  Anemia, Aplastic (23)  ·  Purpura (23)

Broader conditions

Hemic and Lymphatic Diseases (1007)  ·  Cytopenia (995)  ·  Blood Platelet Disorders (994)  ·  Hematologic Diseases (972)  ·  Pathological Conditions, Signs and Symptoms (647)  ·  Pathologic Processes (637)  ·  Thrombotic Microangiopathies (588)  ·  Signs and Symptoms (563)  ·  Blood Coagulation Disorders (556)  ·  Immune System Diseases (554)  ·  Skin Manifestations (548)  ·  Hemorrhage (542)  ·  Purpura (529)  ·  Purpura, Thrombocytopenic (519)

Interventions

eltrombopag (104)  ·  romiplostim (53)  ·  Dexamethasone (49)  ·  Rituximab (47)  ·  avatrombopag (41)  ·  Thrombopoietin (21)  ·  Immunoglobulins, Intravenous (19)  ·  Blood Specimen Collection (18)  ·  Prednisone (17)  ·  eculizumab (15)  ·  Cyclosporine (12)  ·  Danazol (12)  ·  Platelet Transfusion (12)  ·  Sirolimus (12)  ·  fostamatinib (12)

Sponsors

Peking University People's Hospital (54)  ·  Shandong University (44)  ·  Institute of Hematology & Blood Diseases Hospital, China (39)  ·  GlaxoSmithKline (28)  ·  Amgen (26)  ·  Novartis Pharmaceuticals (24)  ·  Alexion Pharmaceuticals, Inc. (21)  ·  Assistance Publique - Hôpitaux de Paris (19)  ·  National Heart, Lung, and Blood Institute (NHLBI) (18)  ·  Assiut University (17)  ·  Eisai Inc. (13)  ·  University Hospital, Bordeaux (13)  ·  Weill Medical College of Cornell University (12)  ·  Sohag University (11)  ·  Takeda (11)

Countries

United States (318)  ·  China (271)  ·  France (144)  ·  Italy (111)  ·  United Kingdom (101)  ·  Germany (99)  ·  Spain (89)  ·  Canada (66)  ·  Poland (61)  ·  Netherlands (54)  ·  Australia (53)  ·  Japan (49)  ·  South Korea (47)  ·  Austria (46)  ·  Belgium (42)

Top investigators

Lei Zhang, MD (18)  ·  Xiao-Hui Zhang, MD (14)  ·  Xiaohui Zhang, MD (10)  ·  Ming Hou, Dr (6)  ·  Ming Hou (5)  ·  Ming Hou, Dr. (5)  ·  Cindy Leissinger, MD (4)

Results publications

PMID 33783815, PMID 19005182, PMID 19846889, PMID 29958797, PMID 40277027, PMID 19671919, PMID 23738544, PMID 24802773, PMID 29419434, PMID 29674506, PMID 34219224, PMID 24254965, PMID 26231455, PMID 26688484, PMID 33995988, PMID 34724566, PMID 12944568, PMID 17077333, PMID 18242413, PMID 20546023, PMID 21533818, PMID 22067384, PMID 22117897, PMID 22409309, PMID 22494019, PMID 23293082, PMID 23470153, PMID 23492914, PMID 24802775, PMID 25566808, PMID 26480931, PMID 27658437, PMID 27734464, PMID 29042367, PMID 29536526, PMID 29778606, PMID 30992268, PMID 32047671, PMID 33031789, PMID 33275766, PMID 33632264, PMID 33881463, PMID 34452956, PMID 34794687, PMID 35030255, PMID 39874521, PMID 10758304, PMID 10786961, PMID 10801186, PMID 10939559

NIH funding

2023 (12), 2018 (7), 2019 (7), 2014 (6), U01HL072268 (5), 2016 (4), 2017 (4), 2025 (3), 2009 (2), 2015 (2), P01HL046925 (2), P30CA016672 (2), 2004 (1), K23HL151882 (1), P01CA015396 (1)